Jordan Lerner-Ellis1,2,3,4, Talia Donenberg5, Humayun Ahmed6,7, Sophia George5, Gilian Wharfe8, Sheray Chin8, Dwight Lowe8, Robert Royer6, Shiyu Zhang6, Steven Narod6,7,9, Judith Hurley5, Mohammad R Akbari10,11,12. 1. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2. Ontario Institute for Cancer Research, Toronto, ON, Canada. 3. Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada. 4. Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada. 5. Sylvester Cancer Center, University of Miami, Miami, FL, USA. 6. Women's College Research Institute, Women's College Hospital, 76 Grenville St.Room 6421, Toronto, ON, M5S 1B2, Canada. 7. Institute of Medical Science, University of Toronto, Toronto, Canada. 8. University of the West Indies, Mona, Jamaica. 9. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. 10. Women's College Research Institute, Women's College Hospital, 76 Grenville St.Room 6421, Toronto, ON, M5S 1B2, Canada. Mohammad.akbari@utoronto.ca. 11. Institute of Medical Science, University of Toronto, Toronto, Canada. Mohammad.akbari@utoronto.ca. 12. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. Mohammad.akbari@utoronto.ca.
Abstract
PURPOSE: Jamaica is an island nation with one of the highest breast cancer incidence rates in the Caribbean (40/100,000 per year). The contribution of cancer susceptibility gene mutations to the burden of breast cancer in Jamaica has not yet been explored. We sought to determine the prevalence of germline mutations in BRCA1, BRCA2, and PALB2 in 179 unselected Jamaican women with breast cancer. METHODS: We sequenced the entire coding regions of BRCA1, BRCA2, and PALB2 for all the study subjects. RESULTS: Overall, 8 of 179 patients (4.5%) had a mutation in one of the three genes: one in BRCA1, two in BRCA2, and five in PALB2. CONCLUSIONS: These data suggest that in addition to BRCA1 and BRCA2, PALB2 should be included in genetic testing for breast cancer patients in Jamaica.
PURPOSE: Jamaica is an island nation with one of the highest breast cancer incidence rates in the Caribbean (40/100,000 per year). The contribution of cancer susceptibility gene mutations to the burden of breast cancer in Jamaica has not yet been explored. We sought to determine the prevalence of germline mutations in BRCA1, BRCA2, and PALB2 in 179 unselected Jamaican women with breast cancer. METHODS: We sequenced the entire coding regions of BRCA1, BRCA2, and PALB2 for all the study subjects. RESULTS: Overall, 8 of 179 patients (4.5%) had a mutation in one of the three genes: one in BRCA1, two in BRCA2, and five in PALB2. CONCLUSIONS: These data suggest that in addition to BRCA1 and BRCA2, PALB2 should be included in genetic testing for breast cancerpatients in Jamaica.
Entities:
Keywords:
BRCA1; BRCA2; Breast cancer; Hereditary; Jamaica; PALB2
Authors: Sheray N Chin; Derria Cornwall; Derek I Mitchell; Michael E McFarlane; Joseph M Plummer Journal: BMC Womens Health Date: 2021-04-23 Impact factor: 2.809